Identification |
Name: | Butanediamide,N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]-,(2R,3S)- |
Synonyms: | Butanediamide,N4-hydroxy-N1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]-,[2R-[1(S*),2R*,3S*]]-;(2S,3R)-5-Methyl-3-[[(aS)-a-(methylcarbamoyl)phenethyl]carbamoyl]-2-[(2-thienylthio)methyl]hexanohydroxamicacid;BB 94;Batimastat; |
CAS: | 130370-60-4 |
Molecular Formula: | C23H31N3O4S2 |
Molecular Weight: | 477.64 |
InChI: | InChI=1/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1 |
Molecular Structure: |
|
Properties |
Density: | 1.25g/cm3 |
Refractive index: | 1.604 |
Biological Activity: | Potent, broad spectrum matrix metalloprotease (MMP) inhibitor (IC 50 values are 3, 4, 4, 6 and 20 nM for MMP -1, -2, -9, -7 and -3 respectively). Exhibits antiproliferative, anti-invasive and antimetastatic activity in human ovarian carcinoma xenografts in vivo . |
Safety Data |
|
|